Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (412)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (325)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 351 to 375 of 424
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Slide sheets for repositioning or moving a person on or from a bed: Late Stage Assessment
Health technology evaluation
28 May 2025
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Technology appraisal guidance
TBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
Technology appraisal guidance
13 August 2025
Somapacitan for treating growth hormone deficiency in children [ID6178]
Technology appraisal guidance
TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]
Technology appraisal guidance
15 October 2025
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Technology appraisal guidance
TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Technology appraisal guidance
26 February 2025
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
Medical technologies guidance
TBC
Sparsentan for treating primary IgA nephropathy [ID6308]
Technology appraisal guidance
30 April 2025
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
Technology appraisal guidance
21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
Technology appraisal guidance
TBC
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
Technology appraisal guidance
19 March 2025
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Technology appraisal guidance
TBC
Surgical vessel sealing systems (MT798)
Medical technologies guidance
TBC
Suspected cancer update
Quality standard
TBC
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
TBC
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
13 August 2025
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Technology appraisal guidance
TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Technology appraisal guidance
15 January 2025
Targeted Muscle Reinnervation for refractory pain after limb amputation
Interventional procedures guidance
20 June 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Technology appraisal guidance
11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Technology appraisal guidance
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Technology appraisal guidance
TBC
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]
Technology appraisal guidance
13 November 2024
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Previous page
1
…
13
14
Current page
15
16
17
Page
15
of
17
Next page
Results per page
10
25
50
All
Back to top